Abbvie Inc


Market Cap$312.22B

Compare Abbvie

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Abbvie IncAbbvie Inc64.83.34%47%5.95.7
marketMarket Avg49.61.28%30%6.11.1
HealthcareHealthcare Avg32.71.25%19%7.40.9

Earnings Call Q4 2023

February 2, 2024 - AI Summary

AbbVie reported strong fourth quarter and full-year 2023 results, with revenues exceeding expectations and growth in the base business excluding Humira.
The company's growth platform, which includes Skyrizi, Rinvoq, Vraylar, Ubrelvy, and Qulipta, delivered double-digit sales growth in 2023 and is expected to continue driving growth in 2024.
AbbVie reaffirmed its long-term sales outlook, including a return to robust revenue growth in 2025 and a high single-digit CAGR through the end of the decade.
The company expects Skyrizi and Rinvoq to collectively exceed $27 billion in sales by 2027, reflecting increased revenue forecasts for both therapies.
AbbVie plans to prioritize investment in its pipeline, with several important R&D programs expected to provide updates and regulatory submissions throughout the year.
The proposed acquisitions of ImmunoGen and Cerevel are anticipated to strengthen AbbVie's oncology and neuroscience pipelines, respectively, providing additional sources of revenue growth.

Target Price by Analysts

4.5% downsideAbbvie Target Price DetailsTarget Price

Current Fair Value

1.8% upside

Undervalued by 1.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$312.22 Billion
Enterprise Value$358.79 Billion
Dividend Yield$5.903 (3.34%)
Earnings per Share$2.72
Outstanding Shares1,766,473,359
Avg 30 Day Volume5,233,377


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio64.78
Price to Sales5.94
Price to Book Ratio35.62
Enterprise Value to Revenue6.61
Enterprise Value to EBIT26.86
Enterprise Value to Net Income74
Total Debt to Enterprise0.17
Debt to Equity5.73

Revenue Sources

No data

ESG Score

No data

About Abbvie Inc

CEO: Richard Gonzalez